Abstract: There is provided a plural dosage form for peptide pharmaceuticals comprising a matrix of gelatin or gelatin derivative having distributed therein the peptide pharmaceutical in particular insulin, as well as, pharmaceutically conventional carriers and additives. By selection of the appropriate gelatin the pharmaceutical is liberated in the small intestine or the large intestine so that is not enzymatically degraded anymore by peptidases.

Abstract: The invention relates to accurately meterable shaped articles, for example granules or pellets, containing hydrophilic macromolecules, active compounds and optionally further pharmaceutically acceptable structure-forming substances and auxiliaries, the active compound being present in a matrix in dissolved, suspended or emulsified form, and a novel process for the production of these shaped articles, the process being particularly economically and ecologically acceptable, and use of the shaped articles as medicaments, in which the bioavailability, shelf life and tolerability is increased. Using the shaped articles or mixtures according to the invention, intermediates or final products for pharmacy, cosmetics, diagnosis, analysis or dietetics (healthcare) can additionally be advantageously prepared.

Abstract: A peroral depot medicament with controlled active substance release is composed of a gelatine matrix that continuously dissolves in an aqueous medium above 37.degree. C., and a medicament distributed therein. The release of the medicament, that may be easily or scarcely soluble, lipophilic or hydrophilic, is variable in time and may be adjusted according to the medicament.

Abstract: A medicament for immediately treating painful, inflammatory and/or febrile diseases contains as active substance ibuprofen as a racemate, as a racemic mixture with its enantiomers, as a pseudoracemate (mixtures of equal parts of S- and R-ibuprofen) or as a mixture of different parts of S- and R-ibuprofen in a range between pure S- and pure R-ibuprofen in the form of a pharmaceutically applicable nanosol and satisfies all requirements of an immediate-effect pharmaceutic form. It can in addition be combined with a slow-release medicament that contains as active substance ibuprofen as a racemic compound, as a pseudoracemate (mixtures of equal parts of S- and R-ibuprofen) or as a mixture of different parts of S- and R-ibuprofen in a range between pure S- and pure R-ibuprofen, in the form of a pharmaceutically applicable, gelatine-based nanosol.

Abstract: Nanosols and process for preparing the same allow colloidally dispersed solutions of scarcely water-soluble active substances to be stabilized with gelatin or its derivatives, by partly or fully setting the iso-ionic point (IIP, equivalent to a neutral charge) between the gelatin and the surface charged active substance particles. In order to neutralize the charge of the system composed of active substance particles and gelatin, the surface charge of the particles is compensated by a corresponding opposite charge of the gelatin molecules. For that purpose, a determined charge in relation to the isoelectric point (IEP) and the pH value of the solution is set on the gelatin molecules. By stabilizing in this way the practically monodispersed state thus generated, the Ostwald maturation of the colloidal particles of scarcely soluble active substance is strongly reduced.

Abstract: Sparingly water-soluble active compounds, for example medicinal substances, are converted into the dissolved (molecularly disperse) state by dissolving them in a hydrophilic peptide having a molecular weight above 100 D, for example gelatin. The solubility both during storage and during use of the formulation by the user or patient is thereby ensured, without organic solvents or solubilizing agents which cause undesirable side effects being required.

Abstract: The invention relates to accurately meterable shaped articles, for example granules or pellets, containing hydrophilic macromolecules, active compounds and optionally further pharmaceutically acceptable structure-forming substances and auxiliaries, the active compound being present in a matrix in dissolved, suspended or emulsified form, and a novel process for the production of these shaped articles, the process being particularly economically and ecologically acceptable, and use of the shaped articles as medicaments, in which the bioavailability, shelf life and tolerability is increased. Using the shaped articles or mixtures according to the invention, intermediates or final products for pharmacy, cosmetics, diagnosis, analysis or dietetics (healthcare) can additionally be advantageously prepared.

Abstract: A peroral administration form for peptidic medicaments contains the peptidic medicament, in particular insulin, distributed in a gelatine or gelatine derivate matrix, besides usual pharmaceutical excipients and additives. By selecting an appropriate gelatine, the medicament is released in the small or large intestine, so that it is no longer enzymatically decomposed by peptidases.

Abstract: Shaped articles containing plant extract(s), in particular pellets, are formed by dispersing the plant extract(s) in a matrix predominantly composed of a skeleton builder, i.e. collagen, gelatin, fractionated gelatin, a collagen hydrolysate, a gelatin derivative, plant protein or plant protein hydrolysate. They are storage-stable, and their pharmacological and cosmetic characteristics are essentially unaltered in comparison with the native extract. They are prepared by a simple process in which liquid plant extract(s) is(are) mixed or emulsified in a solution of the skeleton builder, or solid extracts are dissolved or suspended in a solution of the skeleton builder, the dispersion of skeleton builder and plant extract(s) is added dropwise to an intensely cold, inert, liquefied gas, preferably liquid nitrogen, thus shaping the pellets, and the shaped pellets are dried. The plant extract employed is preferably Aloe vera juice.

Abstract: Immediate-effect medicaments containing a pharmacologically active 2-arylpropionic acid derivate as a pharmaceutically applicable nanosol have a considerably improved action start and bioavailability of the active substance. The 2-arylpropionic acid derivates, for example ibuprofen, flurbiprofen and ketoprofen, that are scarcely soluble in an aqueous medium, are present in a gelatine-stabilized nanosol in a form that allows these active substances to be quickly and completely resorbed already in the stomach. The disclosed colloidal disperse system composed of a 2-arylpropionic acid derivate is prepared by selecting a gelatine or gelatine derivate according to their isoelectric point (IEP), so that their IEP is adapted to the charge of the 2-arylpropionic acid derivate particles, leading to a neutral charge when the gelatine or its derivate is combined with the undissolved 2-arylpropionic acid derivate at a determined pH value.

Abstract: A medicament for immediately treating painful, inflammatory and/or febrile acute diseases contains flurbiprofen as a racemate, a mixture of a racemate with its enantiomers, a pseudoracemate (mixtures of equal parts of S- and R-flurbiprofen) or as a mixture of different parts of S- and R-flurbiprofen in the range extending between pure S and pure R-flurbiprofen as active substance in the form of a pharmaceutically applicable nanosol. This medicament satisfies all requirements of an immediate-effect pharmaceutic form.

Abstract: The invention is directed to exactly dosable molded particles, for example granulates or pellets comprising hydrophilic macromolecules, active materials and additionally further pharmaceutically acceptable skeleton formers and additives wherein the active substance is provided to the matrix, dissolved, suspended or emulsified and a new process for the preparation of such molded particles wherein the process is particularly economically and ecologically unburdensome, as well as the use of such molded particles as pharmaceuticals in which the bioavailability, shelf life, and acceptability ar improved. Furthermore, by means of the molded particles of the present invention, mixtures, intermediates, and end products may be provided for the fields of pharmacy, cosmetics, diagnostics, and analysis and dietetics (health care).

Abstract: Plant extract containing pellets are formed by a dispersion of plant extract or extracts in a matrix, principally comprising a skeleton builder namely collagen, gelatin, fractionated gelatin, a collagen hydrolysate, gelatin derivative plant proteins, or plant protein hydrolysates. They are shelf stable and their pharmacological as well as cosmetic properties are substantially unchanged in comparison to the native extracts. They may be produced by a simple process in which a solution of the skeleton former is mixed with liquid plant extract or emulsified with solid extracts, dissolved or suspended, the dispersion of the skeleton former and the plant extract dropped into a very cold inert fluid, suitably liquid nitrogen, to form the pellets and the thus formed pellets dried.

Abstract: Aloe vera juice containing pellets are formed by a dispersion of aloe vera juice in a matrix, principally comprising a skeleton builder namely collagen, gelatin, fractionated gelatin, a collagen hydrolysate, gelatin derivative, plant proteins, or plant protein hydrolysates. They are shelf stable and their cosmetic as well as pharmacological properties are substantially unchanged in comparison to the native extracts. They may be produced by a simple process in which a solution of the skeleton former is mixed with aloe vera juice extract, the dispersion of the skeleton former and the aloe vera juice into a very cold inert fluid, suitably liquid nitrogen, to form the pellets and the thus formed pellets dried.

Abstract: The present invention is directed to dihydropyridine derivative containing pellets comprising a dispersion of the dihydropyridine derivatives in a matrix which is substantially formed of a skeleton builder such as gelatin, fractionated gelatin, a collagen hydrolysate and/or a gelatin derivative. The invention further directs to a process for the preparation of dihydropyridine derivative containing pellets as well as their use as acute dosage forms against heart/circulatory illnesses.

Abstract: In a dropping procedure for the formation of soft gelatin capsules in which, suitably, a pasty, fluid or sol/gel forming filling material is encapsulated with a soft gelatin mass, the solidification of the soft gelatin mass in a cooling bath of a chemically inert, exceedingly cold fluid which has no negative biological impact nor leaves harmful residue on the soft gelatin capsule. As cooling bath, there is most suitably utilized liquid nitrogen.